Medpace Holdings, Inc.
MEDP · Price history
Price at last available close
$673.79
+$57.85 (+9.39%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Medpace Holdings, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance.
How they make money
Medpace generates revenue by providing full-service clinical contract research organization (CRO) services to the pharmaceutical, biotechnology, and medical device industries. The company enters into service contracts to manage clinical trials, charging fees based on the scope, complexity, and duration of the development programs, which are typically billed as services are performed.
Products & services
Full-service clinical development services including Phase I-IV clinical trials, clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core lab services.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
The company's customer base is concentrated in the biopharmaceutical industry, with 82% of net revenue derived from small biopharmaceutical companies for the year ended December 31, 2025.
Suppliers, materials & equipment
- Clinical trial sites and investigators — Third-party medical facilities and healthcare professionals that conduct clinical trial procedures.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
51
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
82
Strong
Financial Strength
75
Business Quality / Moat
99
Management
100
Growth Quality
40
Risk / Durability
89
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
52
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
57/100
Building Historical Record
Model Score 57/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for MEDP
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can MEDP maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is MEDP's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is MEDP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What future growth or profitability would be needed to justify MEDP's current valuation?
Essential Investment Snapshot
Wall Street Score
51
Opportunity Score
52
Market Cap
$18.85B
P/E Ratio
35.8
EPS
$17.39
52-Week High
$677.90
52-Week Low
$373.00
Beta
1.18
Intrinsic Value
$669.51
Analyst Target
$624.00
Shares Outstanding
29.5M
Total Revenue
$2.78B
Total Debt
$144.1M
Dividend
No current dividend
Liquidation Value / Share
$14.69
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for MEDP
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on MEDP.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Full-service, disciplined operating model.
- +Global platform with broad regulatory and therapeutic expertise.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
- −Dependence on the biopharmaceutical industry and clinical trial spending.
- −Risks associated with international operations and regulatory compliance.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
46
Oct 5, 2026
Change
+4.8
points
Current Score
51
Oct 21, 2026
Category Changes
MEDP increased 4.8 points because Debt improved by 49.8 points, Buffett improved by 12.2 points.
Positive Contributors
- + Debt improved by 49.8 points
- + Buffett improved by 12.2 points
Negative Contributors
- − Valuation declined by 2.1 points
Projected Score
Projected Score
55
Projected Change
+3.7 points
Preliminary comparable-period financial changes suggest improvement of approximately 3.7 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Near Fair ValueCurrent Price
$673.79
Model Intrinsic Value
$669.51
Difference
+$4.27
+0.6% vs IV
Margin of Safety
-0.6%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.78B | $2.53B | $2.11B | $1.89B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.98B | $1.77B | $1.45B | $1.36B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $800.2M | $760.6M | $656.3M | $524.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $189.0M | $197.6M | $180.2M | $161.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $216.8M | $225.7M | $209.4M | $187.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $615.9M | $570.5M | $505.2M | $362.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $583.4M | $534.9M | $446.9M | $336.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $488K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $598.9M | $542.4M | $475.9M | $335.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $107.4M | $91.3M | $71.5M | $52.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $491.5M | $451.1M | $404.4M | $282.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $17.39 | $15.64 | $13.06 | $9.20 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 28.31M | 28.85M | 30.96M | 30.72M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 28.76M | 29.53M | 32.01M | 31.84M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$707.3M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$4.25
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-3.8%
Cash Change
+985.0%
Margin Change
+2.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 17.2%. EPS increased 37.1%. Cash increased 985.0%. Total debt declined 3.8%. Net income margin improved by 2.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
31
Smart Money
31
Number of Gurus
4
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
Here's Why Medpace (MEDP) is a Strong Growth Stock
Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate
Medpace Q3 Earnings Call Highlights
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
Rumor Mill · MEDP
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial